Open Access Article: Inhibition of GABAA receptors by antipsychotics and antidepressants

Many psychotherapeutic drugs, including clozapine, display polypharmacology and act on GABAA receptors. Patients with schizophrenia show alterations in function, structure and molecular composition of the hippocampus, and a recent study demonstrated aberrant levels of hippocampal α5 subunit-containing GABAA receptors.

30-months status of the project and of each work package online meeting

It was time again for a “Status of the Project” meeting. This time the consortium partners came together because we have been working on our objectives for 30 months. In order to enable our colleagues from overseas to participate, the online conference took place in the afternoon.

Open Access Article: Novel method to construct quantitative pharmacophore models

QSAR methods are widely applied in the drug discovery process, both in the hit‐to‐lead and lead optimization phase, as well as in the drug-approval process. Most QSAR algorithms are limited to using molecules as input and disregard pharmacophores or pharmacophoric features entirely.

NeuroDeRisk in silico Toolbox Released Today

The NeuroDeRisk Consortium proudly announces the launch of the NeuroDeRisk in silico Toolbox ! This computational toolbox consists of tools for screening chemical structures and drug candidates against a panel of neurotoxicophore …

18-months status of the project online meeting

It is as if the First Birthday of NeuroDeRisk was celebrated just yesterday and yet it was time for our 18-months meeting, which of course took place online. As always, it was a great pleasure to look into so many happy faces, even if the current situation around the COVID-19 pandemic unfortunately also delays …

First Publication from the NeuroDeRisk Consortium

Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and …

NeuroDeRisk